Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia

A group of 14 schizophrenics who remained symptomatic after neuroleptic treatment received either 0.02 mcg/kg CCK-8 or saline placebo intravenously. Thereafter, 13 received the alternative infusion as a crossover treatment. A second group of 16 such patients received 0.04 mcg/kg CCK-8 or saline intr...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacologia 1987-01, Vol.91 (1), p.80-84
Main Authors: PESELOW, E, ANGRIST, B, SUDILOVSKY, A, CORWIN, J, SIEKIERSKI, J, TRENT, F, ROTROSEN, J
Format: Article
Language:English
Subjects:
Antipsychotic Agents
Applied sciences
Biological and medical sciences
Catecholaminergic system
Clinical Trials as Topic
Double-Blind Method
Exact sciences and technology
Gastrointestinal Diseases - chemically induced
Humans
Medical sciences
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Other techniques and industries
Pharmacology. Drug treatments
Placebos
Schizophrenia - drug therapy
Sincalide - administration & dosage
Sincalide - adverse effects
Sincalide - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A group of 14 schizophrenics who remained symptomatic after neuroleptic treatment received either 0.02 mcg/kg CCK-8 or saline placebo intravenously. Thereafter, 13 received the alternative infusion as a crossover treatment. A second group of 16 such patients received 0.04 mcg/kg CCK-8 or saline intravenously and, thereafter, 14 of these received the alternative infusion as a crossover treatment. Psychopathology was rated prior to, 2-3 h post, and on days 3, 5 and 7 after each infusion. Ratings consisted of the BPRS, the Abrams and Taylor Scale for Emotional Blunting, the Hamilton Anxiety Scale and a Schneiderian "Positive" symptom scale abstracted from the President State Examination. Parallel groups and cross over design analyses failed to show efficacy for CCK-8.
ISSN:0033-3158
1432-2072
DOI:10.1007/BF00690931